DeutschNewstral
Article
Mmarketwatch.com on 2023-02-28 23:13
Novavax stock sheds a quarter of its value after hours as business in 'substantial doubt'2 min read
Related news
Novavax Stock Plunges 25% As Vaccine Maker Has ‘Substantial Doubt’ About Staying In BusinessForbes- BNovavax Says 'Substantial Doubt' Around Its Ability to Continue Operations3 min readbarrons.com
- FCoronavirus latest: Novavax delays vaccine approval plans to third quarterft.com
Novavax shares jump on news of narrowed first-quarter lossesbizjournals.com- MJuniper Networks casts doubt on fourth-quarter sales, marginsmarketwatch.com
- BThe Market’s Cheapest Stocks Offer Substantial Value. 8 Companies to Consider.5 min readbarrons.com
- BThe Market’s Cheapest Stocks Offer Substantial Value. 8 Companies to Consider5 min readbarrons.com
- Novavax reports 'first profitable quarter' amid Covid-19 vaccine work, but misses revenue forecastsbizjournals.com
- Novavax reports 'first profitable quarter' amid global Covid-19 vaccine momentumbizjournals.com
- Why Novavax' CEO called last quarter 'the most significant' in corporate historybizjournals.com
CEO: Novavax to seek US authorization of its Covid vaccine in third quarterCNN
Shares of Community Health lose a quarter of their valuewkrg.com- MRed Lion Hotels stock sheds half its value, making search for new CEO 'necessary'marketwatch.com
- MArm's stock falls again, sheds $8 billion in market value in 3 days2 min readmarketwatch.com
- MStocks in focus: Reata Pharmaceuticals stock soars after FDA-drug approval; Novavax falls after vaccine maker issues ‘substantial doubts’ over future operations2 min readmarketwatch.com
Sears: ‘Substantial doubt’ about futureThe Columbian- MNovavax (NVAX) earnings report This fall 2023mvtelegraph.com
- MNovavax says its Covid vaccine is 90% efficient, plans to submit knowledge to FDA in third quartermvtelegraph.com
Apple sheds $44bn market valuevanguardngr.com
WeWork warns of ‘substantial doubt’ about futurejournalrecord.com